Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer

• Published in: Cancer medicine (Malden, MA) Vol. 7; no. 11; pp. 5655 - 5664
• Main Authors: Jin, Yingji, Choi, Jae Woong, Kim, Hyoung Jin, Eddouzi, Jamel, Kim, Seung Cheol, Ju, Woong, Kim, Yun Hwan, Kim, Hong‐Jin
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2018; John Wiley and Sons Inc; Wiley
• Subjects: Adult; Aged; Aged, 80 and over; Antibodies; Antibodies, Viral - blood; Antigens; anti‐HPV antibody; Cancer Biology; Cervical cancer; Cervical Intraepithelial Neoplasia - immunology; Cervical Intraepithelial Neoplasia - virology; Cervix; Deoxyribonucleic acid; DNA; DNA, Viral - genetics; DNA-Binding Proteins - immunology; E7 and L1; Epidemiology; Female; Human papillomavirus; Humans; Immunoglobulins; Middle Aged; Oncogene Proteins, Viral - immunology; Original Research; Papillomaviridae - genetics; Papillomaviridae - immunology; Papillomavirus E7 Proteins - immunology; Papillomavirus Infections - immunology; Repressor Proteins - immunology; Seroepidemiologic Studies; Serology; Sero‐epidemiology; Uterine Cervical Neoplasms - immunology; Uterine Cervical Neoplasms - virology; Young Adult; United States > US; East Asia; E7 and L1; E6; cervical cancer; Sero-epidemiology; anti-HPV antibody
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.1810

Sero‐epidemiological studies of human papillomavirus (HPV) have been undertaken over the last two decades. In this study, the prevalences of nine serum antibodies (anti‐E6, E7 and L1 antibodies of HPV types 16, 18, and 58) were evaluated in normal (control) Korean women and women with cervical intraepithelial neoplasia (CIN) I, CIN II, CIN III, and cervical cancer. The frequencies of all types of anti‐HPV antibodies were higher in the CIN stages and cervical cancer than in normal women, and those of anti‐HPV16 E6 and E7, anti‐HPV18 E6 and E7, and anti‐HPV58 E7 antibodies were higher in the cervical cancer group than in the CIN stages. The frequencies of antibodies against HPV16, 18, and 58 E7 tended to increase with increasing severity of cervical lesions. However, there were few differences in the frequencies of antibodies against the L1 antigens of HPV16, 18 and 58 in cervical cancer versus CIN stages. The anti‐HPV antibodies were detected in 26.5% of normal, 46.3% of CIN I, 62.5% of CIN II, 51.6% of CIN III, and 75% of cancers when any of the nine antigens was used as a criterion. Correlations between HPV DNA positivity and seropositivity for anti‐HPV E6, E7, or L1 antibodies were found only in HPV16 DNA‐positive cervical cancers for anti‐HPV16 E6 and L1 antibodies. In addition, strong positive correlations in seropositivity were found between anti‐HPV16 E7 and anti‐HPV58 E7 antibodies, and between anti‐HPV18 E6 and anti‐HPV58 E6 antibodies. These findings should advance global profiling of the seroprevalences of antibodies against HPV antigens. In the present study, the prevalences of nine types of anti‐HPV antibodies (anti‐E6, E7, and L1 antibodies of HPV types 16, 18, and 58) were evaluated in normal (control), CIN I, CIN II, CIN III, and cervical cancer. The frequencies of nine types of anti‐HPV antibodies were higher in the CIN stages and cervical cancer than in normal women. It appeared that the frequencies of anti‐HPV16 E6 and E7, anti‐HPV18 E6 and E7, and anti‐HPV58 E7 antibodies were higher in the cervical cancer group than in the CIN stages. However, there were few differences in the frequencies of anti‐HPV 16, 18, and 58 L1 antibodies in cervical cancer vs CIN stages.